Aclarion Inc. (NASDAQ: ACON, ACONW) reported scan volumes for its Nociscan platform increased 196% year-over-year in the first quarter of 2026, according to a company statement.

The healthcare technology company also recorded 64% sequential scan volume growth compared to the fourth quarter of 2025. The growth stemmed from new account activation and increased utilization at existing sites.

The company announced a $2.5 million share repurchase program and reported $19.0 million in cash with no debt as of March 31, 2026. Aclarion had 2,444,871 common shares outstanding as of the quarter end.

Three major UK private insurers - Vitality, AXA, and Aviva - have been reimbursing Nociscan for several months. The company launched a direct-to-patient campaign in the UK and continues engaging with US payers for coverage pathways.

Aclarion's intellectual property portfolio expanded to 64 issued and pending patents worldwide, including a newly issued patent covering AI use in future product workflows. The company operates seven ongoing clinical trials and multiple investigator-initiated studies.

The CLARITY randomized trial, designed to validate Nociscan's clinical utility, expects a preliminary internal readout in the second half of 2026 with public disclosure of interim results in late 2026.

Nociscan uses magnetic resonance spectroscopy data to help physicians identify painful discs in the lumbar spine. The company estimates approximately 5.8 million lumbar MRIs are performed annually in the US for low back pain, representing what it describes as a potential $2 billion market opportunity.

Based on current operating plans and the share buyback program, Aclarion believes its cash resources will fund operations into the second half of 2027.